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ABSTRACT 
Background: Very low birth weight infants «1500 g) frequently require blood 
transfusions because of repeated blood sampling accompanied by anemia of prematurity. 
Methods: In an attempt to identify the effect of human recombinant erythropoi­
etin to decrease the requirement for blood transfusions, erythropoietin was adminis­
tered to 24 pre term infants less than 1500 g prospectively from September 1999 till Decem­
ber 2000. 
Data about the characteristics of the population, the severity of diseases, and 
treatment with erythropoietin, clinical diagnosis, initial and subsequent hemoglobin, vol­
ume of blood loss, and the number of blood transfusions were recorded. These results 
were compared with data from the recorded information of 49 infants who did not 
receive erythropoietin during those past 2 years. There were no differences between 
the 2 groups with regard to the gestational age, birth weight, clinical diagnosis, severity 
of the illness, primary causes of admission, and initial hematologic parameters such as 
hemoglobin, hematocrit and reticulocytes. Erythropoietin was administered in a dose of 
200 rulkg three times weekly for 6-8 weeks accompanied with iron supplement 6 mg/ 
kg/day. Transfusions were administered according to protocoL 
Results: There was no significant difference between the number of blood trans­
fusion among these 2 groups (p= 0. 07). However, transfusions in the erythropoietin 
treated group were fewer in comparison to the other group (1. 9 +/-1.6 to 3. 2 +/-1.1). 
Tel 098- 21- 66937565, Fax 098- 21- 66930024 
Volume 19 
Number 1 
Spring 1384 
May 2005 
Correspondence: Maliheh Kadivar, M.D., Associate Professor, 
Tehran University of Medical Sciences, Department of Pediatrics­
Division of Neonatology, Children's Medical Center, 62 Gharib Street, 
14194 Tehran- Iran, kadivarm@sina.tums.ac.ir 
Abbreviations: rHuEPO, Recombinant human erythropoietin; EPO, 
Erythropoietin; Hb, Hemoglobin; AOP, Anemia of prematurity; BT, 
Blood transfusion; VLBW, Very low birth weight 
!1 
rHuEPO Therapy and Blood Transfusion in VLBW Infants 
No difference was observed between final hemoglobin and hematocrit levels among 
the two groups (10.3 +/- 0.9 vs. 10.4 +/- 0.7 and 33.7 +/- 2.3 vs. 32.2 +/- 2. 2). 
Conclusion: Very low birth weight infants receive frequent blood transfusions but 
a reduction in transfusion requirements was not apparent after administration of eryth­
ropoietin and iron in preterm infants in this study. However, the lack of impact on 
transfusion requirements fails to support routine use of erythropoietin. 
MJIRI, Vol. 19, No.1, 1-5,2005. 
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INTRODUCTION 
Critically sick preterm infants experience more blood 
loss during daily phlebotomy that may equal 5-10% of 
their total blood volume.1.2 Such losses and associated 
anemia routinely result in repeated blood transfusions. 
The anemia of prematurity is aggravated by this iatro­
genic anemia, resulting in more transfusion requirements. 
50-80% of preterm infants with birth weight less than 
1500 g require multiple transfusions.2 Such transfusions 
often exceed the total blood volume of these infants and 
expose them to multiple blood donors.1.2,3 There is a high 
frequency of acquisition of transfusion related infection 
such as cytomegalovirus, hepatitis virus, and human im­
munodeficiency virus. Also frequent BT may be associ­
ated with bronchopulmonary dysplasia, the retinopathy 
of prematurity, and necrotizing enterocolitis.4•5 There are 
great efforts to reduce the use of blood products and 
the complications arising from their use in preterm in­
fants by rHuEPO.6 Several studies reported variable de­
grees of success after administration of EPO.4.6.89 We 
sought whether the administration of rHuEPO to VLB W 
infants results in fewer transfusions. 
PATIENTS AND METHODS 
24 VLBW infants entered into the study after taking 
informed consent from their parents. Patients were eli­
gible if they weighed less than 1500 g at birth, were less 
than 32 weeks' gestation, survived after 72 hours, and 
clinical stability at time of entry as judged by absence of 
seiZLIre, good oxygenation with or without assisted ven­
tilation. Patients were ineligible if they had a major con­
genital anomaly or evidence of coagulopathy. This study 
was conducted prospectively in level 2 and 3 nurseries 
of Aliasghar Children's Hospital which is affiliated to 
Iran University of Medical Sciences, from Septemberl999 
till December 2000. 
These infants were assigned to receive rHuEPO 200 
IU/kg three times weekly within the first weeks of life by 
intravenous infusion or subcutaneously when intrave­
nous was not available. We used rHuEPO ([EPREX] Cilag 
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AG, Zug, Switzerland) as buffered solution containing 
2000 IU/mL of rHuEPO. Treatment continued until dis­
charge or 34 completed weeks. Ferrous sulfate at a dose 
of 2 mg elemental iron/kg/day was given after 2 w eeks if 
they received at least 50% energy intake ora11y and gradu­
ally increased t o  6 mg elemental iron/kg/day after they 
became full fed. All infants received folate supplement 
in doses of l mg every other day and multivitamin prepa­
ration. Clinical data were recorded prospectively and 
include gestational age, birth weight, gender, age and 
weight at the time of study, phlebotomy loss, volume 
and number of BT, clinical diagnosis, severity index of 
diseases, and result of head ultrasound. For study pur­
poses hematologic parameters were checked weekly (full 
blood count and reticulocytes). Special attention was 
paid to Hb, Hct, and reticulocytes at time of admission, 
before rHuEPO therapy, at time of discharge, and in the 
follow up at three months after birth. 
To match the erythropoietin popUlation trials records 
of 49 preterm infants with gestational age less than 32 
weeks and birth weight of less than 1500 g were gath­
ered from admission in the neonatal ward during the two 
previous years. They had also received multivitamin 
preparation, folate supplement and ferrous sulfate. The 
decisions for B T were deri ved from the experience of the 
physicians treating the infants. Infants who were under 
mechanical ventilation were given BT if their Hct fell 
below 40%. Spontaneous breathing infants whose frac­
tion of inspired oxygen was less than OAO were given 
BT if they had signs of anemia with a Hct concentration 
below 30%. Indications for BT were an Hct concentra­
tion below 27% or otherwise at the discretion of the phy­
sician according to symptoms and signs of the patients 
regarding receiving mechanical ventilation, concentra­
tion of oxygen administration, cardiorespiratory status, 
and amount of blood sampling at a same time. 
A power analysis (with two-sided significance 
level of 0.05 and a power of 80%) determined that a 
sample size of approximately 20 infants was needed 
to detect 50% reduction in transfusion in the EPO 
group. Statistical analysis was unpaired Student's 
test t-test for normally distri buted data, M a n n-
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RESULTS W hitney U test for non-parametric variables, and 
li near regressi on. Statistical analyses were per­
formed using microcomputer software (SPSS release 
11.5, SPSS, Inc., Chicago, IL). 
A total of 104 i nfants <32 weeks gestation and < 1500 
g birth weight were adIllitted during the study time (1997-
Table I. Patient characteristics. 
Parameters 
Sex 
Boys (%) 
Girls (%) 
Gestational age (wk) 
(Min.-Max.) 
Birth weight (g) 
(Min.-Max.) 
Age at admission (days) 
(Min.-Max.) 
Ventilatory support (days) 
(Min.-Max.) 
Length of stay (days) 
(Min.-Max.) 
* Parameters: mean±SD 
** Significant p value < 0.05 
EPOgroup 
(24) 
10 (42%) 
14 (58%) 
29.7 +1- 1.5 
(26-32) 
1158.7 +1- 204 
(780-1450) 
2.1+1- 1.4 
(1-6) 
2.4 +1- 2.7 
(0-9) 
22.5 +1- 6.7 
(12-56) 
Table II. Baseline clinical data before and after treatment. 
Parameters* 
Initial Hemoglobin 
Initial Hematocrit 
Discharge Hemoglobin 
Discharge Hematocrit 
Follow up Hemoglobin 
Follow up Hematocrit 
Reticulocytes at time of admission 
Reticulocytes at time of discharge 
Phlebotomy loss (mL/kg) 
Number of cases transfused 
Number receiving 1 blood transfusion** 
Number of blood transfusions 
Transfusion volume (mL)** 
Transfusion volume (mL/kg)** 
Transfusion volume (mL/pt)** 
* Parameters: mean±SD 
** Significantp value < 0.05 
EPOgroup 
(24) 
14.8±1.6 
49.1±4.3 
1O.3±0.9 
33.7±2.3 
1O.6±0.9 
33.6±2.2 
1.3±0.7 
1.3±0.4 
16.5±5.4 
13 (54%) 
6 (5%) 
1.9±1.6 
300 
51 
23 
Without EPO group 
(49) 
24(51 %) 
25(58) 
29.5 +1- 1.6 
(27-32) 
1146.3 +1-149 
(860-1480) 
1.5 +1- 0.9 
(1-5) 
2.3 +1- 2.6 
(0-8) 
20.9 +1- 9.2 
(12-39) 
Without EPO group 
(49) 
14.6±O.9 
48.5±3.2 
1O.4±O.7 
32.3±2.1 
9.8±O.7 
32.2±1.8 
1.2±O.6 
1.2±O.5 
16.3±3.8 
38 (76%) 
7 (14%) 
3.2±1.1 
1368 
64 
38 
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rHuEPO Therapy and Blood Transfusion in VLBW Infants 
2000), and 79 met eligibility criteria. Characteristics of 24 
EPO recipients and 49 c9mparing infants without EPO 
therapy are shown in Table r. There were no significant 
differences between control and study groups with re­
gard to birth weight (1146.3 +/-149g vs. 1158.7+/-204 g), 
gestational age (29.7 weeks+/-1.5 vs. 29.5+/-1.6 weeks), 
sex (male/female: 49%/51 % vs. 42% /58%), duration of 
hospitalization (22.5+/-6.7 days vs. 20.9+/-9.2 days), and 
Hb value at birth (14.6+/-0.9 vs. 14.8+/-1.6). Phlebotomy 
losses, number and volume of transfusions given from 
birth to discharge, and hematologic parameters are 
shown in Table II. The primary causes of admission were 
mostly due to respiratory problems such as respiratory 
distress syndromeiRD$) and pneumonia in both groups 
(83.3% in control group vs. 77.7% in case group) which 
was not significant between the two groups (p<0.05). 
Other problems like sepsis, necrotizing enterocolitis 
(NEC) and metabolic disorders were found among the 
remainder. 
A comparison of the' infants who received rHuEPO 
and the controls, revealed no significant decrease in the 
number of BTs (p= 0.07), but a statistically significant 
decrease in the total volume of transfused red packed 
cells (p= 0.004) was noted. The decrease of the total num­
ber of transfused red blood cells was 1.9 times +/- 1.6 
(from 1 to 5 times) in the infants who received rHuEPO, 
and 3.2 times +/- 1.1 (from 1 to 7 times) in the other group. 
77% of the BTs were within the first 3 weeks of life. The 
increment of Hb concentration and Hct percents after 
rHuEPO administration were not statistically significant 
between the two groups (p= 1.15 and p=0.09). In addi­
tion the reticulocyte count comparison between these 
two groups did not reveal significant changes after dis­
charge from hospital (p= 0.8). No correlation was ob­
served among the different variables such as birth 
weight, gestational age, severity of diseases, clinical 
diagnosis, duration of hospitalization, volume of blood 
sampling, and last Hb and Hct during treatment and be­
tween the two groups. A follow up of 3 months after 
completion of rHuEPO treatment revealed neither any 
decrease in Hb concentration nor need for BT. 
DISCUSSION 
Extremely low birth weight (ELBW) infants frequently 
undergo transfusions because they are critically ill, of­
ten need artificial ventilation, and have the highest blood 
loss in relation to their weight. 1,2,4 Premature infants are 
among the most frequently transfused groups of pa­
tients, usually receiving packed red cells. The immatu­
rity of the immune system, its lesser ability to cope with 
a metabolic load and the presence of maternal antibod­
ies, all complicate the picture. Conservation of blood to 
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minimize losses and the need 'for replacement transfu­
sion is an important strategy that has already been suc­
cessful in reducing the need for transfusion in neonatal 
units. Administration of erythropoietin provides another 
strategy for reducing the need for transfusion especially 
among the sickest patients who require the most BTs 
because of repeated daily sampling. The main concern 
is the long-term consequences of transfusion.5,8 During 
the last decade the transIusion guidelines were changed 
many times to become more restrictive because of com­
plications of BT.3,4,12 
Human recombinant erythropoietin was first cloned 
in 1985, and is currently available for clinical use for a 
variety of anemias including anemia of preterm infants. 10 
Since the initial report in 1990 to treat the anemia of pre­
maturity by rHuEPO administration, numerous clinical 
trials have reported various levels of success in this re­
gard.4,6.8.9 Most recently, ery.thropoietin has been used 
in the first weeks of life in an attempt to prevent the 
anemia of prematurity. 13 The aim of r HuEPO administra­
tion is to prevent and treat anemia in preterm infants and 
reduce the need for transfusions?,5.9 
Questions remain about the optimal dose of rHuEPO, 
and the best time to start treatment.4.6.14,15 Data suggest 
a dose of 300-1200 IU/kglwk causes significant stimula­
tion of erythropoiesis.6,lo,l1 In our study the dose of 
rHuEPO was within these ranges. 
Iron deficiency anemia has been frequently observed 
in preterm infants because of rapidly decreasing iron 
and ferritin plasma levels after initiation of rHuEPO 
therapy.6,8,12.16 The dosage of concomitant iron adminis­
tration with rHuEPO varies from 6-12 mg/kg/day in dif­
ferent studies.6,16 A dose of 6 mg/kg/day seemed to be 
adequate in our patients to avoid limiting erythropoiesis 
and depleting iron stores. 
There are also reports from the influence of protein 
deficiency on the effectiveness of the EPO.15 With initia­
tion and continuation of the feeding we tried to supply 
the protein requirement of the study infants. On the other 
hand the synergistic effect of folate on rHuEPO treat­
ment has been reported which was administered to these 
patients.6.11•15 
The duration of rHuEPO treatment in studies ranges 
from 10 days to 8 weeks.6,7,9 In our study the age at start­
ing rHuEPO was from 6 to 15 days which continued over 
3 to 7 weeks. The results showed a statistically signifi­
cant decrease in the total volume of transfused packed 
red cells among the infants who had received rHuEPO. 
In spite of this, some infants of the groups who received 
rHuEPO needed as many transfusions or more than the 
control group. However, there was a less statistically 
significant reduction in the number of BT. Despite this 
finding the risk of exposure of infants to multiple blood 
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transfusions was reduced by near 40%. The EPO therapy 
was started within the fir�t week in most of our patients. 
The meta-analysis according to the time of initiation of 
EPO therapy on BT suggests that beginning rHuEPO 
treatment during the first week of life is less effective in 
early transfusion than late transfusion. \5,17 The majority 
of BTs were given during the first 3 weeks of life (77%). 
On the other hand such treatment is not likely to elimi­
nate transfusions among VLBW infants completely. 
It has been estimated that most of the BT for ELBW 
infants are required to replace iatrogenic blood loss for 
laboratory tests.1,4,13 Because of the way of blood sam­
pling here in comparison to many developed countries 
(arterial puncturesys._1Jlicroassays) the total amount of 
blood loss adjusted to the weight and length of hospi­
talization was very considerable. In comparison to some 
of the previous studies, measurements of serum iron, 
ferritin, and albumin were not considered because of the 
risk of iatrogenic blood loss. 
Finally, although rHuEPO administration is benefi­
cial for the stimulation of erythropoiesis and correction 
of anemia of prematurity, strict phlebotomy and transfu­
sion criteria could minimize the need for rHuEPO. How­
ever, on the basis of the results of this study, the early 
use of EPO to reduce the number of transfusions in in­
fants is not warranted. 
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